AdipoGen Life Sciences offers a broad range of FNDC4, FNDC5 and Irisin research reagents, including Recombinant Proteins, Antibodies and ELISA Kits.
FNDC5/Irisin & FNDC4 – Members of the FNDC Protein Family
SURAMIN – A Multifunctional Small Molecule with over 100 Years of History
Suramin is a multifunctional molecule with a wide array of potential applications, from parasitic and viral diseases to cancer, snakebite and autism.
Resiniferatoxin (RTX) – Potent TRPV1 Agonist for Pain Relief
The plant Euphorbia resinifera contains the most potent irritant known so far. It was isolated and identified as resiniferatoxin (RTX).
Manumycin A – Exosome Biogenesis Inhibitor
Manumycin A is an inhibitor of exosome biogenesis & secretion. Targeting exosome biogenesis could exert RAS signalling inhibitors’ anticancer effects.
Nano Vaccines Induce T Cell Immunity and Control of Tumour Growth
Using nanoparticle technology in making vaccines for infectious diseases/cancer is advancing & enhances the immunogenicity of some vaccine candidates.
LEADGENE® Indoxyl Sulfate ELISA Kit: Rapid Detection and Surveillance of Chronic Kidney Disease
LEADGENE® Indoxyl Sulfate ELISA Kit is the first CE-registered antibody-based assay tool for chronic kidney disease (CKD) on the global market.
Leadgene Utilizes LEADSPHERE™ Lyophilization Technology to Make Reagents Stable for Long-Term Logistics – Press release
Leadgene Biomedical has announced the launch of LEADSPHERE™ Lyophilization Technology to aid in the dispense, storage, and transport of their reagents
Future Fields’ Fly-Based Growth Factors Earn Sustainable ACT Label from My Green Lab
Future Fields’ serum-free growth factors have achieved the ACT Environmental Impact Factor Label from My Green Lab.
Popular Targets for Bispecific Antibody Drugs
Bispecific Antibody drugs gained popularity since approval of blinatumomab. 6 bsAb drugs are approved by the US FDA/EMA & 180+ are in clinical trials.
Research Grade Biosimilar Antibodies from ProSci
Therapeutic antibodies dominate pipelines and top selling drugs at major pharmaceutical companies. They have proven to be valuable tools in the fight against diseases from cancer and autoimmune disorders to infectious and neurodegenerative diseases. Beyond therapeutics, monoclonal antibodies shown to